Falnidamol (BIBX1382) is a selective epidermal growth factor receptor (EGFR) inhibitor, By inhibiting the signaling of mitogen-activated protein kinases (MAPKs), it plays an anticancer role in human head and neck squamous cell carcinoma in vitro and in vivo.

 

Brand: BCM

 

Melting Point: >217°C (dec.)

 

Boiling Point: 552.0±60.0 °C(Predicted)

 

Target: EGFR

 

Signaling Pathways: Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: CN1CCC(CC1)NC2=NC=C3C(=N2)C(=NC=N3)NC4=CC(=C(C=C4)F)Cl  

 

InChIKey: FTFRZXFNZVCRSK-UHFFFAOYSA-N  

 

InChI: InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)

 

Attribute
[Chem Name]	N8-(3-chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine
[Synonym]	BIBX 1382; BIBX1382; BIBX-1382; BIBX 1382BS; BIBX1382BS; BIBX-1382BS; Falnidamol
[CAS No.]	196612-93-8
[MDL No.]	MFCD09838900
[Formula]	C18H19ClFN7
[Molecular]	387.84
[Form]	Pale Yellow to Yellow Solid
[Storage]	Keep in dark place,Inert atmosphere,2-8°C

Goods Tag